Medibact GuidesShop at Medibact

Stacking Module

MOTS-c Stacking Module

MOTS-c is the most-searched mitochondrial peptide and sits at the centre of the longevity/metabolic stacking cluster. Its distinguishing stacking feature is that it acts on intracellular signaling rather than a surface receptor, which means the usual receptor-collision reasoning does not apply — but a different overlap question does.

MOTS-c Guide at MedibactMOTS-c calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking MOTS-c

  • The human record behind any MOTS-c stack is empty. On 2026-09-18 DailyMed held no MOTS-c label, PubMed held no paper reporting MOTS-c given to a person, and the one registered trial that administers it (NCT07505745, 120 planned participants, 12 weeks) states no milligram figure. The nearest human data are for CohBar's analogue CB4211, 25 mg daily for four weeks in 20 people with fatty liver per the company's 2021 release — a different molecule.
  • Stacked from separate vials, the arithmetic is per vial and never shared. MOTS-c vials are labelled 5 mg and 10 mg; at 5 mg/mL a 5 mg amount fills a U-100 syringe (100 units) and at 10 mg/mL it is 50 units. The vendor figures that circulate, 5 to 10 mg a week over two or three injections, are milligram amounts, while a partner such as SS-31 or Epithalon is counted on its own vial's concentration — one syringe reading does not translate to the other.
  • MOTS-c is a mitochondrial-derived peptide reported to activate AMPK. Because it acts on an intracellular energy-sensing pathway, receptor-level redundancy is not the relevant test — pathway-level overlap is.
  • It is explicitly prohibited by WADA as an AMPK activator. For anyone subject to testing that governs regardless of stack rationale.
  • It is studied at substantially higher amounts than receptor-binding peptides, so its milligram figures do not transfer to or from the GH-axis compounds.
  • No controlled trial has studied MOTS-c combined with anything, and no published human PK exists.

Combinations in detail

Mitochondrial support stack

MOTS-c + SS-31
Why it is proposed
The most coherent pairing here on mechanism: MOTS-c is reported to act through AMPK signaling while SS-31 targets cardiolipin on the inner mitochondrial membrane — a structural rather than a signaling target.
What is reported in practice
Reported as separate vials, commonly concurrent.
Cautions specific to this combination
Both have limited human data; SS-31's clinical programme has produced mixed results. No combination evidence.

Metabolic / longevity stack

MOTS-c + 5-Amino-1MQ
Why it is proposed
Both are discussed for metabolic and body-composition contexts through different routes — AMPK signaling versus NNMT inhibition.
What is reported in practice
Reported concurrently; 5-Amino-1MQ's predominant reported route is oral rather than injected.
Cautions specific to this combination
5-Amino-1MQ's human evidence is essentially absent, and specific pharmacokinetic figures circulating for it could not be verified against peer-reviewed sources. Treat confident claims about it sceptically.

Cellular-aging stack

MOTS-c + Epithalon
Why it is proposed
Community-reported longevity pairing combining mitochondrial signaling with the Khavinson telomerase-oriented bioregulator.
What is reported in practice
Reported concurrently or in alternating courses, following Epithalon's short-course convention.
Cautions specific to this combination
Epithalon's evidence base is concentrated in one research tradition with no controlled human telomere trials. The pairing's rationale is thematic rather than mechanistic.

GLP-1 weight-management stack

MOTS-c + Tirzepatide or Retatrutide
Why it is proposed
Reported alongside metabolic programmes on the premise that mitochondrial and incretin mechanisms are unrelated.
What is reported in practice
Separate vials on separate schedules.
Cautions specific to this combination
The incretin compounds carry documented hypoglycaemia interactions, and adding an AMPK activator that influences glucose uptake to a glucose-lowering therapy is not mechanistically neutral. This warrants clinical input rather than community reasoning.

What to avoid, and why

  • Assuming absence of receptor overlap means absence of interaction — MOTS-c influences glucose handling, which matters when stacked with glucose-lowering medicines.
  • Carrying MOTS-c's milligram figures across to receptor-binding peptides dosed in micrograms.
  • Competing under anti-doping rules; MOTS-c is explicitly WADA-prohibited.

Related reading

MOTS-c dosage recordMOTS-c reconstitution mathHow peptide stacks are builtEvery stack we cover

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.